EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Bibliometric Analysis via CiteSpace from 2000 to 2022

Jinbin Xu, ZhanSen Huang, ShunTian Gao, GengGuo Deng, Jinming Di

Urologia Internationalis · 2023

DOI: 10.1159/000531322 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Urologia Internationalis, 2023. Verfasst von Jinbin Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: The aim of the study was to identify the cooperation of authors, countries, institutions and explore the hot spots regarding research of tyrosine kinase inhibitors (TKIs) for renal cell carcinoma (RCC) treatment in the past 22 years. Summary: Relevant original and review articles were obtained from the Web of Science Core Collection from 2000 to 2022. CiteSpace software was used to perform the visualization of scientific productivity and emerging trends. Network maps were generated to evaluate the collaborations between different authors, countries, institutions, and keywords. Key Messages: A total of 4,951 articles related to TKI for RCC treatment were identified. We observed a gradual increase in the number of publications from 2000 to 2022. The USA dominated the field in all countries, and Mem Sloan Kettering Cancer Centre (USA) had more extensive cooperating relationships with other institutions. Motzer RJ and Escudier B were two of the authority scholars in this specific field with the most publications and co-citations. Journal of Clinical Oncology had the most citations of all the journals. A total of 10 major clusters were explored based on the reference co-citation analysis. From 2000 to 2022, the research hot spots have undergone two dramatic shifts during 2006 and 2019, respectively, relevant topics were TKI and TKI combined with immune checkpoint inhibitors (CPIs). At present, the research hot spots focus on CPI and targeted therapies. Bibliometric analysis is allowing researchers to recognize the current research status by providing a comprehensive overview of the development of scientific literature related to TKI for RCC treatment, and information for further research be demonstrated as well.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansTyrosine Kinase InhibitorsBibliometricsMedical Oncology

Stichwörter der Autor:innen

Bibliometric analysisCiteSpaceImmune checkpoint inhibitorsRenal cell carcinomaTyrosine kinase inhibitors

Substanzen

Tyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Zitieren

APA

Xu, J., Huang, Z., Gao, S., Deng, G., & Di, J. (2023). Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Bibliometric Analysis via CiteSpace from 2000 to 2022. Urologia Internationalis. https://doi.org/10.1159/000531322

Vancouver

Xu J, Huang Z, Gao S, Deng G, Di J. Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Bibliometric Analysis via CiteSpace from 2000 to 2022. Urologia Internationalis. 2023. doi:10.1159/000531322

BibTeX
@article{Xu2023,
  author = {Xu, Jinbin and Huang, ZhanSen and Gao, ShunTian and Deng, GengGuo and Di, Jinming},
  title = {Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Bibliometric Analysis via CiteSpace from 2000 to 2022},
  journal = {Urologia Internationalis},
  year = {2023},
  doi = {10.1159/000531322}
}
Kostenlos starten →